Granted Patent
B2
US 12,297,285 · App. 17/853,576 · Granted May 13, 2025
Circular RNA encoding chimeric antigen receptors targeting BCMA
Inventors:
Thomas Barnes (Watertown, MA); Amy M. Becker (Watertown, MA); Brian Goodman (Watertown, MA); Jui Dutta-Simmons (Watertown, MA)
Assignee:
Orna Therapeutics, Inc.
C07K16/2878A61K47/28A61K47/6929A61K48/0033A61P35/00C07K14/7051C07K16/2803A61K38/00A61K39/00C07K2319/00
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Circular RNA, along with related compositions and methods are described herein. In some embodiments, the inventive circular RNA comprises group I intron fragments, spacers, an IRES, duplex forming regions, and an expression sequence. In some embodiments, the expression sequence encodes an antigen. In some embodiments, circular RNA of the invention has improved expression, functional stability, immunogenicity, ease of manufacturing, and/or half-life when compared to linear RNA. In some embodiments, inventive methods and constructs result in improved circularization efficiency, splicing efficiency, and/or purity when compared to existing RNA circularization approaches.
Claims (40)
1. A precursor RNA polynucleotide comprising:
a. a 3′ group I intron fragment
b. a core functional element, and
c. a 5′ group I intron fragment,
wherein the core functional element comprises:
i. a translation initiation element (TIE) comprising an internal ribosome entry (IRES) comprising a polynucleotide having at least 95% sequence identity to SEQ ID NO: 1284 or a functional fragment thereof, and
ii. a polynucleotide encoding an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 3691 or a functional fragment thereof.
2. The precursor RNA polynucleotide of claim 1 , wherein the TIE further comprises a UTR or a fragment thereof, an aptamer complex or a fragment thereof, or a combination thereof.
3. The precursor RNA of claim 1 , wherein the 3′ group I intron fragment comprises a first or a first and a second nucleotide of a 3′ group I intron splice site dinucleotide.
4. The precursor RNA of claim 1 , wherein the 5′ group I intron fragment comprises a first or a first and a second nucleotide of a 5′ group I intron splice site dinucleotide.
5. A circular RNA polynucleotide comprising a TIE and a polynucleotide encoding an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 3691 or a functional fragment thereof, wherein the TIE comprises an IRES comprising a polynucleotide having at least 95% sequence identity to SEQ ID NO: 1284 or a functional fragment thereof.
6. The circular RNA polynucleotide of claim 5 , further comprising a polynucleotide comprising a sequence encoding a CAR comprising an antigen binding molecule that specifically binds to CD19.
7. The circular RNA polynucleotide of claim 5 , wherein the polynucleotide encoding the amino acid sequence is codon optimized.
8. The circular RNA polynucleotide of claim 5 , wherein the CAR comprises an amino acid sequence of SEQ ID NO: 3690.
9. The circular RNA polynucleotide of claim 5 , wherein the circular RNA is formed from a precursor RNA polynucleotide that was transcribed from a vector or DNA comprising a PCR product, a linearized plasmid, non-linearized plasmid, linearized minicircle, a non-linearized minicircle, viral vector, cosmid, ceDNA, or an artificial chromosome.
10. The circular RNA polynucleotide of claim 5 , further comprising an internal spacer sequence.
11. The circular RNA polynucleotide of claim 5 , further comprising 1 to 100 natural nucleotides derived from a natural exon.
12. A pharmaceutical composition comprising:
the circular RNA polynucleotide of claim 5 ; and
b. a nanoparticle, and optionally, a targeting moiety operably connected to the nanoparticle.
13. The pharmaceutical composition of claim 12 , wherein the nanoparticle is a lipid nanoparticle, a core-shell particle, or a biodegradable nanoparticle.
14. The pharmaceutical composition of claim 12 , wherein the nanoparticle comprises one or more cationic lipids, ionizable lipids, or poly β-amino esters.
15. The pharmaceutical composition of claim 12 , wherein the nanoparticle comprises one or more non-cationic lipids.
16. The pharmaceutical composition of claim 12 , wherein the nanoparticle comprises one or more PEG-modified lipids, polyglutamic acid lipids, or hyaluronic acid lipids.
17. The pharmaceutical composition of claim 12 , wherein the nanoparticle comprises cholesterol.
18. The pharmaceutical composition of claim 12 , wherein the nanoparticle comprises arachidonic acid, leukotriene, or oleic acid.
19. A method of treating a cancer in a subject in need thereof comprising administering a therapeutically effective amount of a composition comprising the circular RNA of claim 5 , a lipid nanoparticle, and optionally, a targeting moiety operably connected to the nanoparticle.
20. The method of claim 19 , wherein the subject has a cancer selected from the group consisting of: acute myeloid leukemia (AML); alveolar rhabdomyosarcoma; B cell malignancies; bladder cancer; bone cancer; brain cancer; breast cancer; cancer of the anus, anal canal, or anorectum; cancer of the eye; cancer of the intrahepatic bile duct; cancer of the joints; cancer of the neck; gallbladder cancer; cancer of the pleura; cancer of the nose, nasal cavity, or middle ear; cancer of the oral cavity; cancer of the vulva; chronic lymphocytic leukemia; chronic myeloid cancer; colon cancer; esophageal cancer, cervical cancer; fibrosarcoma; gastrointestinal carcinoid tumor; head and neck cancer; Hodgkin lymphoma; hypopharynx cancer; kidney cancer; larynx cancer; leukemia; liquid tumors; lipoma; liver cancer; lung cancer; lymphoma; mesothelioma; mastocytoma; melanoma; multiple myeloma; nasopharynx cancer; non-Hodgkin lymphoma; B-chronic lymphocytic leukemia; hairy cell leukemia; Burkitt's lymphoma; ovarian cancer; pancreatic cancer; cancer of the peritoneum; cancer of the omentum; mesentery cancer; pharynx cancer; prostate cancer; rectal cancer; renal cancer; skin cancer; small intestine cancer; soft tissue cancer; solid tumors; synovial sarcoma; gastric cancer; teratoma; testicular cancer; thyroid cancer; and ureter cancer.
21. A eukaryotic cell comprising a circular RNA polynucleotide according to claim 5 .
22. The eukaryotic cell of claim 21 , wherein the eukaryotic cell is an immune cell.
23. The eukaryotic cell of claim 21 , wherein the eukaryotic cell is a T cell, dendritic cell, macrophage, B cell, neutrophil or basophil.
24. The precursor RNA polynucleotide of claim 1 , wherein the IRES has 100% sequence identity to SEQ ID NO: 1284 or a functional fragment thereof.
25. The precursor RNA polynucleotide of claim 1 , wherein the amino acid sequence has 100% sequence identity to SEQ ID NO: 3691 or a functional fragment thereof.
26. The circular RNA polynucleotide of claim 5 , wherein the IRES has 100% sequence identity to SEQ ID NO: 1284 or a functional fragment thereof.
27. The circular RNA polynucleotide of claim 5 , wherein the amino acid sequence has 100% sequence identity to SEQ ID NO: 3691 or a functional fragment thereof.
28. The precursor RNA polynucleotide of claim 1 , wherein the precursor RNA polynucleotide further comprises a stop codon or a stop cassette.
29. The precursor RNA polynucleotide of claim 1 , wherein the IRES has 100% sequence identity to SEQ ID NO: 1284.
30. The precursor RNA polynucleotide of claim 1 , wherein the amino acid sequence has 100% sequence identity to SEQ ID NO: 3691.
31. The circular RNA polynucleotide of claim 9 , wherein the IRES has 100% sequence identity to SEQ ID NO: 1284.
32. The circular RNA polynucleotide of claim 9 , wherein the amino acid sequence has 100% sequence identity to SEQ ID NO: 3691.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 20, 2023
From: DUTTA-SIMMONS, JUI
To: ORNA THERAPEUTICS, INC.
Reel/Frame 065615/0824 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 15, 2023
From: BARNES, THOMAS; BECKER, AMY M.; GOODMAN, BRIAN
To: ORNA THERAPEUTICS, INC.
Reel/Frame 063647/0129 →
Continuity (2)
Provisional Application
63355527
· Jun 24, 2022
References Cited (388)
US 3832253A
· Di et al.
· 1974
[cited by applicant]
US 3854480A
· Zaffaroni
· 1974
[cited by applicant]
US 4235871A
· Papahadjopoulos et al.
· 1980
[cited by applicant]
US 4323689A
· Vogel et al.
· 1982
[cited by applicant]
US 4450150A
· Sidman
· 1984
[cited by applicant]
US 4452775A
· Kent
· 1984
[cited by applicant]
US 4501728A
· Geho et al.
· 1985
[cited by applicant]
US 4661450A
· Kempe et al.
· 1987
[cited by applicant]
US 4667014A
· Nestor, Jr. et al.
· 1987
[cited by applicant]
US 4737323A
· Martin et al.
· 1988
[cited by applicant]
US 4748034A
· de Rham
· 1988
[cited by applicant]
US 4837028A
· Allen
· 1989
[cited by applicant]
US 4897355A
· Eppstein et al.
· 1990
[cited by applicant]
US 5019369A
· Presant et al.
· 1991
[cited by applicant]
US 5075109A
· Tice et al.
· 1991
[cited by applicant]
US 5087616A
· Myers et al.
· 1992
[cited by applicant]
US 5171678A
· Behr et al.
· 1992
[cited by applicant]
US 5239660A
· Ooi
· 1993
[cited by applicant]
US 5334761A
· Gebeyehu et al.
· 1994
[cited by applicant]
US 5434261A
· Schoen et al.
· 1995
[cited by applicant]
US 5580859A
· Felgner et al.
· 1996
[cited by applicant]
US 5591737A
· Doherty et al.
· 1997
[cited by applicant]
US 5625047A
· Been et al.
· 1997
[cited by applicant]
US 5629304A
· Murakata et al.
· 1997
[cited by applicant]
US 5656606A
· Nargund et al.
· 1997
[cited by applicant]
US 5672596A
· Wyvratt et al.
· 1997
[cited by applicant]
US 5712128A
· Been et al.
· 1998
[cited by applicant]
US 5744335A
· Wolff et al.
· 1998
[cited by applicant]
US 5747485A
· Doherty et al.
· 1998
[cited by applicant]
US 5755903A
· Garant et al.
· 1998
[cited by applicant]
US 5766903A
· Sarnow
· 1998
[cited by applicant]
US 5773244A
· Ares, Jr. et al.
· 1998
[cited by applicant]
US 5885613A
· Holland et al.
· 1999
[cited by applicant]
US 5948902A
· Honkanen et al.
· 1999
[cited by applicant]
US 5972964A
· Perregaard
· 1999
[cited by applicant]
US 6043026A
· Patchett et al.
· 2000
[cited by applicant]
US 6210931B1
· Feldstein et al.
· 2001
[cited by applicant]
US 6211174B1
· Devita et al.
· 2001
[cited by applicant]
US 6319494B1
· Capon et al.
· 2001
[cited by applicant]
US 6368802B1
· Kool
· 2002
[cited by applicant]
US 6417326B1
· Cullis et al.
· 2002
[cited by applicant]
US 6576628B1
· Grams et al.
· 2003
[cited by applicant]
US 6620597B1
· Chen et al.
· 2003
[cited by applicant]
US 7709226B2
· Foote
· 2010
[cited by applicant]
US 7741465B1
· Eshhar et al.
· 2010
[cited by applicant]
US 8158601B2
· Chen et al.
· 2012
[cited by applicant]
US 8829170B2
· Dale et al.
· 2014
[cited by applicant]
US 9708628B2
· Tange et al.
· 2017
[cited by applicant]
US 9765022B2
· Xu et al.
· 2017
[cited by applicant]
US 20040014194A1
· Beyer et al.
· 2004
[cited by applicant]
US 20100137407A1
· Abe et al.
· 2010
[cited by applicant]
US 20100305197A1
· Che
· 2010
[cited by applicant]
US 20160194368A1
· Hoge et al.
· 2016
[cited by applicant]
US 20180010175A1
· Cheng
· 2018
[cited by applicant]
US 20180153822A1
· Karve et al.
· 2018
[cited by applicant]
US 20180311343A1
· Huang et al.
· 2018
[cited by applicant]
US 20190290694A1
· Gautron et al.
· 2019
[cited by applicant]
US 20190314291A1
· Besin et al.
· 2019
[cited by applicant]
US 20200040370A1
· Eber et al.
· 2020
[cited by applicant]
US 20230226096A1
· Goodman et al.
· 2023
[cited by applicant]
CN 101016264A
· 2007
[cited by applicant]
CN 105176981A
· 2015
[cited by applicant]
CN 106801050A
· 2017
[cited by applicant]
EP 2819377A1
· 2014
[cited by applicant]
EP 3630966A1
· 2020
[cited by applicant]
EP 3819377A1
· 2021
[cited by applicant]
GB 2308064A
· 1997
[cited by applicant]
JP 2016521133A
· 2016
[cited by applicant]
JP 2017043556A
· 2017
[cited by applicant]
JP 6284181B2
· 2018
[cited by applicant]
KR 20110095439A
· 2011
[cited by applicant]
WO WO1995011029A1
· 1995
[cited by applicant]
WO WO1995024207A1
· 1995
[cited by applicant]
WO WO1999055743A1
· 1999
[cited by applicant]
WO WO2005044201A2
· 2005
[cited by applicant]
WO WO2005079803A1
· 2005
[cited by applicant]
WO WO2005121348A1
· 2005
[cited by applicant]
WO WO2006138380A2
· 2006
[cited by applicant]
WO WO2007044627A2
· 2007
[cited by applicant]
WO WO2008103276A2
· 2008
[cited by applicant]
WO WO2009035541A1
· 2009
[cited by applicant]
WO WO2010042877A1
· 2010
[cited by applicant]
WO WO2010053572A2
· 2010
[cited by applicant]
WO WO2010084371A1
· 2010
[cited by applicant]
WO WO2010138652A1
· 2010
[cited by applicant]
WO WO2010138659A1
· 2010
[cited by applicant]
WO WO2010138685A1
· 2010
[cited by applicant]
WO WO2010138695A1
· 2010
[cited by applicant]
WO WO2010138706A1
· 2010
[cited by applicant]
WO WO2010138758A1
· 2010
[cited by applicant]
WO WO2011068810A1
· 2011
[cited by applicant]
WO WO2011075656A1
· 2011
[cited by applicant]
WO WO2011127255A1
· 2011
[cited by applicant]
WO WO2012099755A1
· 2012
[cited by applicant]
WO WO2012170889A1
· 2012
[cited by applicant]
WO WO2012170930A1
· 2012
[cited by applicant]
WO WO2013012476A2
· 2013
[cited by applicant]
WO WO2013076509A1
· 2013
[cited by applicant]
WO WO2013118878A1
· 2013
[cited by applicant]
WO WO2013149140A1
· 2013
[cited by applicant]
WO WO2014144871A1
· 2014
[cited by applicant]
WO WO2014186334A1
· 2014
[cited by applicant]
WO WO2014193857A1
· 2014
[cited by applicant]
WO WO2015034925A1
· 2015
[cited by applicant]
WO WO2015095340A1
· 2015
[cited by applicant]
WO WO2015130584A2
· 2015
[cited by applicant]
WO WO2016020373A1
· 2016
[cited by applicant]
WO WO2016197121A1
· 2016
[cited by applicant]
WO WO2017046203A1
· 2017
[cited by applicant]
WO WO2017049245A2
· 2017
[cited by applicant]
WO WO2017055487A2
· 2017
[cited by applicant]
WO WO2017059357A1
· 2017
[cited by applicant]
WO WO2017099823A1
· 2017
[cited by applicant]
WO WO2017112865A1
· 2017
[cited by applicant]
WO WO2017118734A1
· 2017
[cited by applicant]
WO WO2017172698A1
· 2017
[cited by applicant]
WO WO2017185054A1
· 2017
[cited by applicant]
WO WO2017201332A1
· 2017
[cited by applicant]
WO WO2017201333A1
· 2017
[cited by applicant]
WO WO2017201340A2
· 2017
[cited by applicant]
WO WO2017201342A1
· 2017
[cited by applicant]
WO WO2017201346A1
· 2017
[cited by applicant]
WO WO2017201348A1
· 2017
[cited by applicant]
WO WO2017201349A1
· 2017
[cited by applicant]
WO WO2017201350A1
· 2017
[cited by applicant]
WO WO2017222911A1
· 2017
[cited by applicant]
WO WO2018144775A1
· 2018
[cited by applicant]
WO WO2018157009A1
· 2018
[cited by applicant]
WO WO2018170260A1
· 2018
[cited by applicant]
WO WO2018170306A1
· 2018
[cited by applicant]
WO WO2018191722A1
· 2018
[cited by applicant]
WO WO2018222890A1
· 2018
[cited by applicant]
WO WO2018237372A1
· 2018
[cited by applicant]
WO WO2019067999A1
· 2019
[cited by applicant]
WO WO2019089828A1
· 2019
[cited by applicant]
WO WO2019118919A1
· 2019
[cited by applicant]
WO WO2019152557A1
· 2019
[cited by applicant]
WO WO2019152848A1
· 2019
[cited by applicant]
WO WO2019191780A1
· 2019
[cited by applicant]
WO WO2019213308A1
· 2019
[cited by applicant]
WO WO2019222275A2
· 2019
[cited by applicant]
WO WO2019236673A1
· 2019
[cited by applicant]
WO WO2020010242A1
· 2020
[cited by applicant]
WO WO2020023595A1
· 2020
[cited by applicant]
WO WO2020035070A1
· 2020
[cited by applicant]
WO WO2020061367A1
· 2020
[cited by applicant]
WO WO2020198403A2
· 2020
[cited by applicant]
WO WO2020237227A1
· 2020
[cited by examiner]
WO WO2020252436A1
· 2020
[cited by applicant]
WO WO2021041541A1
· 2021
[cited by applicant]
WO WO2021055849A1
· 2021
[cited by applicant]
WO WO2021113777A2
· 2021
[cited by examiner]
WO WO2022261490A2
· 2022
[cited by examiner]
Al-Lazikani et al. “Standard conformations for the canonical structures of immunoglobulins,” J Mol Biol, 1997, 273(4):927-48.
[cited by applicant]
Badelt et al. “Computational Design of a Circular RNA with Prionlike Behavior,” Artif Life., 2016, 22(2):172-84.
[cited by applicant]
Bail et al. “Tri- to be mono- for bacterial mRNA decay,” Structure, 2009, 17(3):317-9.
[cited by applicant]
Barretina et al. “The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity,” Nature, 2012, 483(7391):603-7.
[cited by applicant]
Barrett et al. “Circular RNAs: analysis, expression and potential functions,” Development, 2016, 1143(11):1838-47.
[cited by applicant]
Behr et al. “Efficient gene transfer into mammalian primary endocrine cells with lipopolyamine-coated DNA,” PNAS 1989, 86(18):6982-6986.
[cited by applicant]
Bloomfield. “Quasi-Elastic Light Scattering Applications in Biochemistry and Biology,” Ann. Rev. Biophys. Bioeng., 1981, 10:421-50.
[cited by applicant]
Bohjanen, et al., “A small circular TAR RNA decoy specifically inhibits Tat-activated HIV-1 transcription,”, Nucleic Acids Res., 1996, 24(19):3733-8.
[cited by applicant]
Bohjanen, et al., “TAR RNA decoys inhibit Tat-activated HIV-1 transcription after preinitiation complex formation”, Nucleic Acids Res., 1997, 25(22): 4481-6.
[cited by applicant]
Borchardt et al. “Inducing circular RNA formation using the CRISPR endoribonuclease Csy4,” RNA, 2017, 23(5):619-627.
[cited by applicant]
Branch et al. “Unusual properties of two branched RNA's with circular and linear components,” Nucleic Acids Res., 1985, 13(13):4889-903.
[cited by applicant]
Bricogne. “[23] Bayesian statistical viewpoint on structure determination: Basic concepts and examples,” Methods Enzymol, 1997, 276:361-423.
[cited by applicant]
Bricogne. “Direct phase determination by entropy maximization and likelihood ranking: status report and perspectives,” Acta Crystallogr D Biol Crystallogr, 1993, 49(Pt 1):37-60.
[cited by applicant]
Brown et al. “Biophotonic cytotoxicity assay for high-throughput screening of cytolytic killing,” J Immunol Methods, 2005, 297(1-2):39-52.
[cited by applicant]
Budker et al. “Protein/Amphipathic Polyamine Complexes Enable Highly Efficient Transfection with Minimal Toxicity,” BioTechniques, 1997, 23:139-147.
[cited by applicant]
Cao et al. “Development and application of a multiplexable flow cytometry-based assay to quantify cell-mediated cytolysis,” Cytometry A, 2010, 77(6):534-45.
[cited by applicant]
Caplen et al. “In vitro liposome-mediated DNA transfection of epithelial cell lines using the cationic liposome DC-Chol/DOPE,” Gene Ther, 1995, 2(9):603-13.
[cited by applicant]
Carmona, Ellese Marie. 2019. Circular RNA: Design Criteria for Optimal Therapeutical Utility. Doctoral dissertation, Harvard University, Graduate School of Arts & Sciences.
[cited by applicant]
Cech, “Self-Splicing of Group 1 Introns,” Annu Rev Biochem., 1990, 59:543-68.
[cited by applicant]
Chayen. “The role of oil in macromolecular crystallization,” Structure, 1997, 5(10):1269-74.
[cited by applicant]
Chen and Sarnow, “Initiation of protein synthesis by the eukaryotic translational apparatus on circular RNAs,” Science. 1995, 268(5209):415-417.
[cited by applicant]
Chen et al. “Promising diagnostic and therapeutic circRNAs for skeletal and chondral disorders,” Int J Biol Sci., 2021, 17(5):1428-1439.
[cited by applicant]
Chen et al. “Sensing Self and Foreign Circular RNAs by Intron Identify,” Molecular Cell, 2017, 67:228-238.
[cited by applicant]
Cheung et al. “Epitope-specific antibody response to the surface antigen of duck hepatitis B virus in infected ducks,” Virology, 1990, 176(2):546-52.
[cited by applicant]
Chothia et al. “Canonical structures for the hypervariable regions of immunoglobulins,” J Mol Biol, 1987, 196(4):901-17.
[cited by applicant]
Chothia et al. “Structural repertoire of the human VH segments,” J Mol Biol, 1992, 227(3):799-817.
[cited by applicant]
Costello et al. “Reinventing the Wheel: Synthetic Circular RNAs for Mammalian Cell Engineering.” Trends Biotechnol., 2020, 38(2):217-230.
[cited by applicant]
Dahlman et al., “Barcoded nanoparticles for high throughput in vivo discovery of targeted therapeutics,” Proc Natl Acad Sci U S A. 2017, 114(8):2060-2065.
[cited by applicant]
Devaux et al., “Circular RNAs in heart failure”, Eur J Heart Fail. 2017, 19(6):701-709.
[cited by applicant]
Dobrikova et al. “Activity of a type 1 picornavirus internal ribosomal entry site is determined by sequences within the 3? nontranslated region,” PNAS, 2003, 100(25):15125-15130.
[cited by applicant]
Dong et al. “Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates,” PNAS, 2014, 111(11):3955-3960.
[cited by applicant]
Durymanov and Reineke, “Non-viral Delivery of Nucleic Acids: Insight Into Mechanisms of Overcoming Intracellular Barriers,” Front Pharmacol. 2018, 9:971.
[cited by applicant]
Eastwood et al. “Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells,” Br J Clin Pharmacol, 2010, 161(3):512-526.
[cited by applicant]
Eastwood et al. “Severity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release,” Br J Clin Pharmacol, 2013, 76(2): 299-315.
[cited by applicant]
Edge et al. “Total synthesis of a human leukocyte interferon gene,” Nature, 1981, 292(5825):756-62.
[cited by applicant]
Examination Report issued in EP19739422.4 dated Mar. 17, 2022. 6 pages.
[cited by applicant]
Felgner et al. “Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure,” PNAS, 1987, 84:7413-7417.
[cited by applicant]
Fenton et al., “Customizable Lipid Nanoparticle Materials for the Delivery of siRNAs and mRNAs,” Angew Chem Int Ed Engl. 2018, 57(41):13582-86.
[cited by applicant]
Final Office Action for U.S. Appl. No. 16/432,177, mailed Apr. 25, 2023.
[cited by applicant]
Final Office Action for U.S. Appl. No. 17/191,697, mailed Sep. 30, 2021.
[cited by applicant]
Final Office Action for U.S. Appl. No. 17/384,460, mailed Jul. 22, 2022.
[cited by applicant]
Final Office Action for U.S. Appl. No. 17/503,208, mailed Aug. 30, 2022.
[cited by applicant]
Final Office Action for U.S. Appl. No. 17/548,241, mailed Sep. 28, 2022.
[cited by applicant]
Final Office Action for U.S. Appl. No. 17/202,223, mailed Mar. 7, 2022.
[cited by applicant]
Final Office Action for U.S. Appl. No. 17/202,223, mailed Nov. 2, 2022.
[cited by applicant]
Finney et al. “Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product,” J Immunol, 1998, 161(6):2791-7.
[cited by applicant]
Ford et al. “Synthesis of circular RNA in bacteria and yeast using RNA cyclase ribozymes derived from a group I intron of phage T4,” PNAS, 1994, 91:3117-3121.
[cited by applicant]
Foster et al. “Purification of mRNA Encoding Chimeric Antigen Receptor Is Critical for Generation of a Robust T-Cell Response,” Hum Gene Ther, 2019, 30(2):168-178.
[cited by applicant]
Gao et al. “A novel cationic liposome reagent for efficient transfection of mammalian cells,” Biochem Biophys Res Commun, 1991, 179(1):280-5.
[cited by applicant]
Garlapati et al. “Identification of a novel internal ribosome entry site in giardiavirus that extends to both sides of the initiation codon,” J Biol Chem, 2004, 279(5):3389-97.
[cited by applicant]
Giegé et al. “Crystallogenesis of biological macromolecules: facts and perspectives,” Acta Crystallogr D Biol Crystallogr, 1994, 50(Pt 4):339-50.
[cited by applicant]
Greene et al., “Circular RNAs: Biogenesis, Function and Role in Human Diseases,” Front Mol Biosci. 2017, 4:38.
[cited by applicant]
Gross et al. “Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy,” Annu Rev Pharmacol Toxicol, 2016, 56:59-83.
[cited by applicant]
Gurtu et al. “IRES bicistronic expression vectors for efficient creation of stable mammalian cell lines,” Biochem Biophys Res Commun, 1996, 229(1):295-8.
[cited by applicant]
Han et al. “Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy,” J Hematol Oncol., 2019, 12(1):128.
[cited by applicant]
Harrer et al. “RNA-transfection of gamma/delta T cells with a chimeric antigen receptor or an alpha/beta T-cell receptor: a safer alternative to genetically engineered alpha/beta T cells for the immunotherapy of melanom…
[cited by applicant]
He et al. “Circular RNAs and cancer”, Cancer Lett . 2017, 396:138-144.
[cited by applicant]
Heyes et al. “Cationic lipid saturation influences intracellular delivery of; encapsulated nucleic acids,” Journal of Controlled Release, 2005, 107:276-287.
[cited by applicant]
Holdt et al. “Circular RNAs as Therapeutic Agents and Targets,” Front Physiol., 2018, 9:1262.
[cited by applicant]
International Preliminary Report on Patentability and Written Opinion for International Application No. PCT/US2019/035531, mailed Dec. 8, 2020, 8 pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2020/034418, mailed Nov. 16, 2021, 8 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2019/035531, mailed Sep. 27, 2019, 13 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2020/034418, mailed Sep. 28, 2020, 15 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2020/063494, mailed Aug. 6, 2021, 24 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2021/023540, mailed Oct. 11, 2021, 30 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2021/031629, mailed Feb. 4, 2022, 24 pages.
[cited by applicant]
International Search Report and Written Opinion for International Appliction No. PCT/US2021/033276, mailed Oct. 18, 2021, 34 pages.
[cited by applicant]
Jay. “A general procedure for the end labeling of proteins and positioning of amino acids in the sequence,” J Biol Chem, 1984, 259(24):15572-8.
[cited by applicant]
Jayaraman et al. “Polymerase chain reaction-mediated gene synthesis: synthesis of a gene coding for isozyme c of horseradish peroxidase,” PNAS, 1991, 88(10):4084-8.
[cited by applicant]
Jeck et al. “Detecting and characterizing circular RNAs,” Nat Biotechnol., 2014, 32(5):453-61.
[cited by applicant]
Jemielity et al. “Synthetic mRNA cap analogs with a modified triphosphate bridge—synthesis, applications and prospects,” New Journal of Chemistry, 2010, 34:829-844.
[cited by applicant]
Kabat et al. “Attempts to locate complementarity-determining residues in the variable positions of light and heavy chains,” Annals of the New York Academy of Sciences, 1971, 190(1):382-393.
[cited by applicant]
Kaczmarek et al. “Advances in the Delivery of RNA Therapeutics: from Concept to Clinical Reality,” Genome Medicine, 2017, 9(1):60.
[cited by applicant]
Kalos et al. “T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia,” Sci Transl Med, 2011, 3:95.
[cited by applicant]
Kariko et al., “Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA,” Nucleic Acids Res. 2011, 39(21):e142.
[cited by applicant]
Kariko et al., “Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability,” Mol Ther. 2008, 16(11):1833-40.
[cited by applicant]
Kauffman et al. “Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in Vivo with Fractional Factorial and Definitive Screening Designs,” Nano Lett, 2015, 15(11):7300-6.
[cited by applicant]
Kauffman et al., “Efficacy and Immunogenicity of Unmodified and Pseudouridine-Modified mRNA Delivered Systemically with Lipid Nanoparticles in Vivo,” Biomaterials, 2016, 109:78-87.
[cited by applicant]
Kauffman et al., “Rapid, Single-cell Analysis and Discovery of Vectored mRNA Transfection in Vivo wth a loxP-Flanked tdTomato Reporter Mouse,” Molecular Therapy: Nucleic Acids, 2018, 10:55-63.
[cited by applicant]
Kauffman, “Optimization and analysis of lipid nanoparticles for in vivo mRNA delivery,” Ph.D. Thesis, Massachusetts Institute of Technology, Department of Chemical Engineering, 2017, 167 pages.
[cited by applicant]
Kaufman et al. “Improved vectors for stable expression of foreign genes in mammalian cells by use of the untranslated leader sequence from EMC virus,” Nucleic Acids Res, 1991, 19(16):4485-90.
[cited by applicant]
Kirkland et al. “Analysis of the fine specificity and cross-reactivity of monoclonal anti-lipid A antibodies,” J Immunol, 1986, 137(11):3614-9.
[cited by applicant]
Klibanov et al. “Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes,” FEBS Lett., 1990, 268(1):235-7.
[cited by applicant]
Kobayashi et al. “Improved dicistronic mRNA expression vectors for efficient selection of transfectants highly expressing foreign genes,” Biotechniques, 1996, 21(3):398-402.
[cited by applicant]
Koos et al. “Influence of structure on antimicrobial activity of some heterocycles. IV. 1-(3-alkylamino-2-hydroxypropyl)-2-methyl-5-nitroimidazoles,” Chem Papers. 1994, 48(1):54-57.
[cited by applicant]
Kotterman and Schaffer. “Engineering adeno-associated viruses for clinical gene therapy,” Nat Rev Genet. 2014, 15(7):445-51.
[cited by applicant]
Krause et al. “Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes,” J Exp Med., 1998, 188(4):619-26.
[cited by applicant]
Lasic et al. “Gelation of liposome interior. A novel method for drug encapsulation,” FEBS Lett, 1992, 312(2-3):255-8.
[cited by applicant]
Lasic. “Novel applications of liposomes,” Trends Biotechnol, 1998, 16(7):307-21.
[cited by applicant]
Legnini et al., “Circ-ZNF609 Is a Circular RNA that Can Be Translated and Functions in Myogenesis,” Mol Cell. 2017, 66(1):22-37.
[cited by applicant]
Lenzi et al., “Gene Transfer Research: The Evolution of the Clinical Science,” National Academies Press (US), 2014. Available from: https://www.ncbi.nlm.nih.gov/books/NBK195893/.
[cited by applicant]
Li et al. “In vivo gene transfer via intravenous administration of cationic lipid-protamine-DNA (LPD) complexes,” Gene Ther, 1997, 4(9):891-900.
[cited by applicant]
Li et al. “The Biogenesis, Functions, and Challenges of Circular RNAs,” Mol Cell., 2018, 71(3):428-442.
[cited by applicant]
Liang et al. “Short intronic repeat sequences facilitate circular RNA production,” Genes & Development, 2014, 28:2233-2247.
[cited by applicant]
Liang et al. “The Output of Protein-Coding Genes Shifts to Circular RNAs When the Pre-mRNA Processing Machinery Is Limiting,” Molecular Cell, 2017, 68:940-954.
[cited by applicant]
Litke et al. “Trans ligation of RNAs to generate hybrid circular RNAs using highly efficient autocatalytic transcripts,” Methods, 2021, S1046-2023(21)00135-3.
[cited by applicant]
Mangraviti et al. “Polymeric nanoparticles for nonviral gene therapy extend brain tumor survival in vivo,” ACS Nano, 2015, 9(2):1236-49.
[cited by applicant]
Mao et al. “Biological roles and therapeutic potential of circular RNAs in osteoarthritis,” Mol Ther Nucleic Acids, 2021, 24:856-867.
[cited by applicant]
McPherson. “Crystallization of proteins from polyethylene glycol,” J Biol Chem., 1976, 251(20):6300-3.
[cited by applicant]
McPherson. “Current approaches to macromolecular crystallization,” Eur J Biochem., 1990, 189(1):1-23.
[cited by applicant]
Meganck et al. “Engineering highly efficient backsplicing and translation of synthetic circRNAs,” Mol Ther Nucleic Acids, 2021, 23:821-834.
[cited by applicant]
Memczak et al., “Circular RNAs and a large class of animal RNAs with regulatory potency,” 2013, 495:333-338.
[cited by applicant]
Merten et al. “Production of lentiviral vectors,” Mol Ther, 2016, 3:16017.
[cited by applicant]
Metzgar et al. “Abrupt emergence of diverse species B adenoviruses at US military recruit training centers,” J Infect Dis. 2007, 196(10):1465-73.
[cited by applicant]
Moldenhauer et al. “Identity of HML-1 antigen on intestinal intraepithelial T cells and of B-ly7 antigen on hairy cell leukaemia,” Scand. J. Immunol., 1990, 32(2):77-82.
[cited by applicant]
Morel et al. “Monoclonal antibodies to bovine serum albumin: Affinity and specificity determinations,” Mol Immunol, 1988, 25(1):7-15.
[cited by applicant]
Morrissey et al. “Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs,” Nat Biotechnol, 2005, 23(8):1002-7.
[cited by applicant]
Mosser et al. “Use of a dicistronic expression cassette encoding the green fluorescent protein for the screening and selection of cells expressing inducible gene products,” Biotechniques, 1997, 22(1):150-4, 156, 158-61.
[cited by applicant]
Mu et al., “An origin of the immunogenicity of in vitro transcribed RNA,” Nucleic Acids Res. 2018, 46(10):5239-5249.
[cited by applicant]
Nakamoto et al. “Chemical Synthesis of Circular RNAs with Phosphoramidate Linkages for Rolling-Circle Translation,” Curr Protoc., 2021, 1(3):e43.
[cited by applicant]
Nambiar et al. “Total synthesis and cloning of a gene coding for the ribonuclease S protein,” Science, 1984, 223(4642):1299-301.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 16/432,177, mailed Oct. 3, 2022.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 17/191,697, mailed Jun. 18, 2021.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 17/374,497, mailed Dec. 7, 2021.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 17/468,100, mailed Dec. 8, 2021.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 17/492,512, mailed Mar. 1, 2022.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 17/894,141, mailed Jan. 18, 2023.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 17/202,223, mailed Apr. 18, 2022.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 17/202,223, mailed Aug. 20, 2021.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 17/384,460, mailed Dec. 23, 2022.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 17/384,460, mailed Mar. 24, 2022.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 17/503,208, mailed May 5, 2022.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 17/548,241, mailed May 24, 2022.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 17/548,247, mailed Apr. 1, 2022.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/202,223, mailed Mar. 2, 2023.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/202,223, mailed Nov. 16, 2022.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/503,208, mailed Jan. 19, 2023.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/548,241, mailed Feb. 27, 2023.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/548,241, mailed Mar. 31, 2023.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/548,241, mailed May 22, 2023.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/548,247, mailed Nov. 14, 2022.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/191,697, mailed Nov. 2, 2021.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/374,497, mailed Apr. 13, 2022.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/374,497, mailed May 4, 2022.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/384,460, mailed Jun. 13, 2023.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/468,100, mailed Apr. 8, 2022.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/468,100, mailed May 3, 2022.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/492,512, mailed Apr. 26, 2022.
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/548,247, mailed Jul. 22, 2022.
[cited by applicant]
Oberli et al. “Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy,” Nano Letters, 2017, 17:1326-1335.
[cited by applicant]
Obi et al. “The design and synthesis of circular RNAs,” Methods, 2021, S1046-2023(21)00065-7.
[cited by applicant]
Ochi et al., “Non-enzymatic in vitro production of circular hammerhead ribozyme targeting the template region of human telomerase RNA,” Nucleic Acids Symp Ser (Oxf). 2009, 53:275-276.
[cited by applicant]
Pamudurti et al., “Translation of CircRNAs,” Mol Cell. 2017, 66(1):9-21.
[cited by applicant]
Petkovic et al. “RNA circularization strategies in vivo and in vitro,” Nucleic Acids Res. 2015, 43(4):2454-65.
[cited by applicant]
Porter et al. “Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia,” N Engl J Med, 2011, 365(8):725-33.
[cited by applicant]
Presolski et al. “Copper-Catalyzed Azide-Alkyne Click Chemistry for Bioconjugation,” Curr Protoc Chem Biol, 2011, 3(4):153-162.
[cited by applicant]
Puttaraju and Been, “Circular Ribozymes Generated in
[cited by applicant]
Puttaraju et al. “Group I Permuted Intron-exon (PIE) Sequences Self-splice to Produce Circular Exons,” Nucleic Acids Research, 1992, 20(20):5357-5364.
[cited by applicant]
Queen et al. “a humanized antibody that binds to the interleukin 2 receptor,” PNAS, 1989, 86:10029-10033.
[cited by applicant]
Rafiq et al. “Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo,” Nat Biotechnol., 2018, 36(9):847-856.
[cited by applicant]
Ramesh et al. “High-titer bicistronic retroviral vectors employing foot-and-mouth disease virus internal ribosome entry site,” Nucleic Acids Res, 1996, 24(14):2697-700.
[cited by applicant]
Rausch et al. “Characterizing and circumventing sequence restrictions for synthesis of circular RNA in vitro,” Nucleic Acids Res., 2021, 49(6):e35.
[cited by applicant]
Rees et al. “Bicistronic vector for the creation of stable mammalian cell lines that predisposes all antibiotic-resistant cells to express recombinant protein,” Biotechniques, 1996, 20(1):102-4, 106, 108-10.
[cited by applicant]
Riechmann et al. “Reshaping human antibodies for therapy,” Nature, 1988, 332(6162):323-7.
[cited by applicant]
Roversi et al. “Modelling prior distributions of atoms for macromolecular refinement and completion,” Acta Crystallogr D Biol Crystallogr, 2000, 56(Pt 10):1316-23.
[cited by applicant]
Sahin et al., “mRNA-based therapeutics—developing a new class of drugs,” Nat Rev Drug Discov. 2014, 13(10):759-80.
[cited by applicant]
Semple et al. “Rational design of cationic lipids for siRNA delivery,” Nat Biotechnol, 2010, 28(2):172-6.
[cited by applicant]
Shim et al., “Nonviral Delivery Systems for Cancer Gene Therapy: Strategies and Challenges,” Curr Gene Ther. 2018, 18(1):3-20.
[cited by applicant]
Shobaki et al. “Mixing lipids to manipulate the ionization status of lipid nanoparticles for specific tissue targeting,” Int J Nanomedicine, 2018, 13:8395-8410.
[cited by applicant]
Song et al. “CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo,” Blood, 2012, 119(3):696-706.
[cited by applicant]
Starke et al. “Exon Circularization Requires Canonical Splice Signals,” Cell Reports, 2015, 10:103-111.
[cited by applicant]
STN Registry Database Entry for 1333432-38-4 entered STN Sep. 27, 2011.
[cited by applicant]
STN Registry Database Entry for 1333626-46-2 entered STN Sep. 28, 2011.
[cited by applicant]
STN Registry Database Entry for 156811-31-3 entered STN Aug. 5, 1994.
[cited by applicant]
STN Registry Database Entry for 157493-54-4 entered STN Sep. 7, 1994.
[cited by applicant]
STN Registry Database Entry for 1609534-48-6 entered STN Jun. 4, 2014.
[cited by applicant]
STN Registry Database Entry for 2086785-24-0 entered STN Mar. 17, 2017.
[cited by applicant]
STN Registry Database Entry for 2086785-25-1 entered STN Mar. 17, 2017.
[cited by applicant]
STN Registry Database Entry for 2086785-26-2 entered STN Mar. 17, 2017.
[cited by applicant]
STN Registry Database Entry for 2086785-27-3 entered STN Mar. 17, 2017.
[cited by applicant]
STN Registry Database Entry for 2086785-32-0 entered STN Mar. 17, 2017.
[cited by applicant]
STN Registry Database Entry for 2086785-33-1 entered STN Mar. 17, 2017.
[cited by applicant]
STN Registry Database Entry for 2089251-16-9 entered STN Apr. 10, 2017.
[cited by applicant]
STN Registry Database Entry for 79111-60-7 entered STN Nov. 16, 1984.
[cited by applicant]
Structures of lipids from Benenato et al., Ciaramella et al., Huang et al., and Benenato et al. (28 pages).
[cited by applicant]
Stähli et al. “Distinction of epitopes by monoclonal antibodies,” Methods Enzymol, 1983, 92:242-53.
[cited by applicant]
Sullenger et al. “From the RNA world to the clinic,” Science, 2016, 352(6292):1417-1420.
[cited by applicant]
Szoka et al. “Comparative properties and methods of preparation of lipid vesicles (liposomes),” Annu Rev Biophys Bioeng, 1980, 9:467-508.
[cited by applicant]
Tramontano et al. “Framework residue 71 is a major determinant of the position and conformation of the second hypervariable region in the VH domains of immunoglobulins,” J Mol Biol, 1990, 215(1):175-82.
[cited by applicant]
Umekage et al. “In vivo circular RNA production using a constitutive promoter for high-level expression,” J Biosci Bioeng, 2009, 108(4):354-6.
[cited by applicant]
Umekage et al., “In Vivo Circular RNA Expression by the Permuted Intron-Exon Method,” InTech, 2012, 17 pages.
[cited by applicant]
Unpublished U.S. Appl. No. 17/996,074, entitled “Circular RNA Compositions and Methods,” filed Oct. 12, 2022; Inventors: Robert Alexander Wesselhoeft and Brian Goodman.
[cited by applicant]
Unpublished U.S. Appl. No. 17/999,378, entitled “Circular RNA Compositions and Methods,” filed Nov. 18, 2022; Inventors: Robert Alexander Wesselhoeft, Thomas Barnes, Brian Goodman, Gregory Motz, Amy M. Becker, and Allen…
[cited by applicant]
Unpublished U.S. Appl. No. 18/069,621, entitled “Circular RNA Compositions and Methods,” filed Dec. 21, 2022; Inventors: Robert Alexander Wesselhoeft, Daniel G. Anderson, Shinichiro Fuse, Brian Goodman, Allen T. Horhota…
[cited by applicant]
Unpublished U.S. Appl. No. 18/320,126, entitled “Circular RNA Compositions and Methods,” filed May 18, 2023; Inventors: Brian Goodman, Robert Alexander Wesselhoeft, Allen T. Horhota, Junghoon Yang.
[cited by applicant]
Valdmanis and Kay, “The Expanding Repertoire of Circular RNAs,” Mol Ther. 2013, 21(6):1112-4.
[cited by applicant]
Van Esch et al. “Aggregation behavior and copper-binding properties of surfactants containing imidazole and pyrazole ligands,” Recl Trav Chim Pays-Bas. 1994, 113(4):186-193.
[cited by applicant]
Verhoeyen et al. “Reshaping human antibodies: grafting an antilysozyme activity,” Science, 1988, 239(4847):1534-6.
[cited by applicant]
Vessillier et al. “Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials—Whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm,” J Immunol Methods, 20…
[cited by applicant]
Wadhwa et al. “Receptor mediated glycotargeting,” J Drug Target, 1995, 3(2):111-27.
[cited by applicant]
Wang and Wang, “Efficient backsplicing produces translatable circular mRNAs,” RNA, 2015, 21(2):172-179.
[cited by applicant]
Wang et al. “Combinatorially designed lipid-like nanoparticles for intracellular delivery of cytotoxic protein for cancer therapy,” Angew Chem Int Ed Engl. 2014, 53(11):2893-2898.
[cited by applicant]
Wesselhoeft et al. “Engineering Circular RNA for Potent and Stable Translation in Eukaryotic Cells,” Nature Communications, 2018, 9(1):2629, 10 pages.
[cited by applicant]
Wesselhoeft et al. “RNA Circulation Diminishes Immunogenicity and can Extend Translation Duration In Vivo,” Molecular Cell, 2019, 74(3):508-520.
[cited by applicant]
Wiesinger et al. “Clinical-Scale Production of CAR-T Cells for the Treatment of Melanoma Patients by mRNA Transfection of a CSPG4-Specific CAR under Full GMP Compliance,” Cancers (Basel), 2019, 11(8):1198.
[cited by applicant]
Xue et al. “Lipid-based nanocarriers for RNA delivery,” Curr Pharm Des, 2015, 21(22):3140-7.
[cited by applicant]
Yang et al. “Circular RNAs: Expression, localization, and therapeutic potentials,” Mol Ther, 2021, 29(5):1683-1702.
[cited by applicant]
Yang et al., “Decay Rates of Human mRNAs: Correlation with Functional Characteristics and Sequence Attributes,” Genome Res. 2003, 13(8):1863-72.
[cited by applicant]
Yeku et al. “Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy,” Biochem Soc Trans, 2016, 44(2):412-8.
[cited by applicant]
Zeng et al., “A Circular RNA Binds to and Activates AKT Phosphorylation and Nuclear Localization Reducing Apoptosis and Enhancing Cardia Repair,” Theranostics, 2017, 7(16):3842-3855.
[cited by applicant]
Zhang et al. “A novel protein encoded by the circular form of the SHPRH gene suppresses glioma tumorigenesis,” Oncogene, 2018, 37(13):1805-1814.
[cited by applicant]
International Search Report and Written Opinion for International Patent Application No. PCT/US2023/068812, mailed Oct. 20, 2023.
[cited by applicant]
Xin, Y., et al., “Developing a Novel Anti-BCina CAR-T for Relapsed or Refractory Multiple Myeloma”, Blood, American Society of Hematology, 134:50, Nov. 13, 2019.
[cited by applicant]
Taewoong, C., et al., “Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma”, Pharmacology & Therapeutics, 232:1-9, Apr. 1, 2022.
[cited by applicant]
Barrett, D.M., et al., “Chimeric Antigen Receptor Therapy for Cancer”, Annual Review of Medicine, 65(1):333-347, Jan. 14, 2014.
[cited by applicant]
Sasso, J.M., et al., “The Progress and Promise of RNA Medicine—An Arsenal of Targeted Treatments”, Journal of Medicinal Chemistry, 65(10):6975-7015, May 26, 2022.
[cited by applicant]